You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeloxicam
Accession NumberDB00814  (APRD00529)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron. [Wikipedia]

Structure
Thumb
Synonyms
Meloxicam
Méloxicam
Meloxicam
Meloxicamum
Mobic
UNII-vg2qf83cgl
External Identifiers
  • UH-AC62
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Meloxicamtablet15 mgoralActavis Pharma Company2004-08-12Not applicableCanada
Act Meloxicamtablet7.5 mgoralActavis Pharma Company2004-08-12Not applicableCanada
Auro-meloxicamtablet15 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-meloxicamtablet7.5 mgoralAuro Pharma Inc2012-10-19Not applicableCanada
Ava-meloxicamtablet7.5 mgoralAvanstra Inc2011-11-082014-08-21Canada
Ava-meloxicamtablet15.0 mgoralAvanstra Inc2011-08-112014-08-21Canada
Dom-meloxicamtablet15 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-meloxicamtablet7.5 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Meloxicamsuspension7.5 mg/5mLoralRoxane Laboratories, Inc.2001-11-01Not applicableUs
Meloxicamtablet15 mgoralPro Doc Limitee2009-06-10Not applicableCanada
Meloxicamtablet7.5 mgoralPro Doc Limitee2009-06-10Not applicableCanada
Meloxicamtablet15 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Meloxicamtablet7.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Meloxicamtablet15 mgoralSanis Health Inc2010-07-26Not applicableCanada
Meloxicamtablet7.5 mgoralSanis Health Inc2010-07-26Not applicableCanada
Mobictablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2000-06-01Not applicableUs
Mobicsuspension7.5 mg/5mLoralBoehringer Ingelheim Pharmaceuticals, Inc.2005-11-01Not applicableUs
Mobictablet15 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-10-01Not applicableUs
Mobictablet7.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-06-01Not applicableUs
Mobicoxtablet15 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2000-09-26Not applicableCanada
Mobicoxtablet7.5 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2000-09-26Not applicableCanada
Mylan-meloxicamtablet15 mgoralMylan Pharmaceuticals Ulc2004-08-11Not applicableCanada
Mylan-meloxicamtablet7.5 mgoralMylan Pharmaceuticals Ulc2004-08-11Not applicableCanada
Nu-meloxicamtablet7.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-meloxicamtablet15.0 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-meloxicamtablet7.5 mgoralPharmel Inc2004-04-06Not applicableCanada
PHL-meloxicamtablet15 mgoralPharmel Inc2004-04-06Not applicableCanada
PMS-meloxicamtablet15 mgoralPharmascience Inc2003-11-07Not applicableCanada
PMS-meloxicamtablet7.5 mgoralPharmascience Inc2003-11-07Not applicableCanada
Ratio-meloxicamtablet15 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-11-112014-09-19Canada
Ratio-meloxicamtablet7.5 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-11-112014-09-19Canada
Teva-meloxicamtablet15 mgoralTeva Canada Limited2004-10-22Not applicableCanada
Teva-meloxicamtablet7.5 mgoralTeva Canada Limited2004-10-22Not applicableCanada
Vivlodexcapsule10 mg/1oralIroko Pharmaceuticals, LLC2015-10-31Not applicableUs
Vivlodexcapsule5 mg/1oralIroko Pharmaceuticals, LLC2015-10-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-meloxicamtablet7.5 mgoralApotex Inc2004-02-13Not applicableCanada
Apo-meloxicamtablet15 mgoralApotex Inc2004-02-13Not applicableCanada
Comfort Pac With MeloxicamkitPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Comfort Pac With MeloxicamkitPd Rx Pharmaceuticals, Inc.2013-07-09Not applicableUs
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2010-04-13Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Meloxicamtablet15 mg/1oralApotex Corp.2006-07-28Not applicableUs
Meloxicamtablet7.5 mg/1oralReady Meds2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralDispensing Solutions, Inc.2009-12-01Not applicableUs
Meloxicamtablet15 mg/1oralSterling Knight Pharmaceuticals, Llc2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2011-08-15Not applicableUs
Meloxicamtablet15 mg/1oralApotex Corp2010-05-14Not applicableUs
Meloxicamtablet7.5 mg/1oralStrides Arcolab Limited2009-05-14Not applicableUs
Meloxicamtablet7.5 mg/1oralLupin Pharmaceuticals, Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralMc Kesson Contract Packaging2011-12-23Not applicableUs
Meloxicamtablet7.5 mg/1oralTeva Pharmaceuticals USA Inc2006-07-20Not applicableUs
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2014-02-19Not applicableUs
Meloxicamtablet7.5 mg/1oralSTAT Rx USA LLC2009-10-05Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-17Not applicableUs
Meloxicamtablet7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-20Not applicableUs
Meloxicamtablet7.5 mg/1oralUnichem Pharmaceuticals (USA), Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMylan Institutional Inc.2006-08-01Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2006-07-01Not applicableUs
Meloxicamtablet7.5 mg/1oralProficient Rx LP2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2006-10-02Not applicableUs
Meloxicamtablet7.5 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-15Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2010-04-23Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-30Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2014-02-01Not applicableUs
Meloxicamtablet7.5 mg/1oralApotex Corp.2006-07-28Not applicableUs
Meloxicamtablet15 mg/1oralReady Meds2012-08-28Not applicableUs
Meloxicamtablet7.5 mg/1oralDispensing Solutions, Inc.2009-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralSterling Knight Pharmaceuticals, Llc2015-12-23Not applicableUs
Meloxicamtablet15 mg/1oralMylan Pharmaceuticals Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralRebel Distributors Corp.2006-12-20Not applicableUs
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-28Not applicableUs
Meloxicamtablet7.5 mg/1oralMylan Institutional Inc.2006-08-01Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2011-01-07Not applicableUs
Meloxicamtablet15 mg/1oralBelcher Pharmaceuticals,LLC2015-06-30Not applicableUs
Meloxicamtablet15 mg/1oralAurobindo Pharma Limited2006-10-02Not applicableUs
Meloxicamtablet15 mg/1oralGlenmark Generics Inc., USA2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2010-06-022015-12-29Us
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2012-10-24Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2011-09-08Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2015-01-02Not applicableUs
Meloxicamtablet15 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Meloxicamtablet7.5 mg/1oralReady Meds2012-08-28Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralCipla USA Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralMylan Pharmaceuticals Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1Rebel Distributors Corp.2006-12-20Not applicableUs
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralUnit Dose Services2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralPhysicians Total Care, Inc.2006-08-07Not applicableUs
Meloxicamtablet15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Meloxicamtablet7.5 mg/1oralAurobindo Pharma Limited2006-10-02Not applicableUs
Meloxicamtablet7.5 mg/1oralGlenmark Generics Inc., USA2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralAv Kare, Inc.2014-09-192015-12-29Us
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2013-08-212016-04-05Us
Meloxicamtablet15 mg/1oralClinical Solutions Wholesale2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2010-10-14Not applicableUs
Meloxicamtablet7.5 mg/1oralCipla USA Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2011-09-02Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Meloxicamtablet15 mg/1oralSTAT Rx USA LLC2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralUnit Dose Services2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralPhysicians Total Care, Inc.2006-08-07Not applicableUs
Meloxicamtablet7.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Meloxicamtablet15 mg/1oralCadila Healthcare Limited2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralZydus Pharmaceuticals (USA) Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralAv Kare, Inc.2014-09-192015-12-29Us
Meloxicamtablet15 mg/1oralKAISER FOUNDATION HOSPITALS2015-07-09Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-23Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Meloxicamtablet7.5 mg/1oralClinical Solutions Wholesale2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralbryant ranch prepack2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Meloxicamtablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralAidarex Pharmaceuticals LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralAv Pak2012-10-09Not applicableUs
Meloxicamtablet7.5 mg/1oralInternational Laboratories, Inc.2008-12-01Not applicableUs
Meloxicamtablet15 mg/1oralCarlsbad Technology, Inc.2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralCadila Healthcare Limited2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Meloxicamtablet7.5 mg/1oralKAISER FOUNDATION HOSPITALS2015-07-09Not applicableUs
Meloxicamtablet7.5 mg/1oralSTAT Rx USA LLC2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2009-07-01Not applicableUs
Meloxicamtablet7.5 mg/1oralbryant ranch prepack2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2016-01-26Not applicableUs
Meloxicamtablet7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralAidarex Pharmaceuticals LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-05-03Not applicableUs
Meloxicamtablet7.5 mg/1oralNorthwind Pharmaceuticals2015-01-05Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2013-11-08Not applicableUs
Meloxicamtablet15 mg/1oralSTAT Rx USA LLC2009-10-05Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2010-10-15Not applicableUs
Meloxicamtablet7.5 mg/1oralApotex Corp2010-05-14Not applicableUs
Meloxicamtablet15 mg/1oralReady Meds2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralCarilion Materials Management2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralLife Line Home Care Services, Inc.2006-08-07Not applicableUs
Meloxicamtablet7.5 mg/1oralAv Pak2012-10-09Not applicableUs
Meloxicamtablet15 mg/1oralInternational Laboratories, Inc.2008-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralCarlsbad Technology, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralStrides Arcolab Limited2009-05-14Not applicableUs
Meloxicamtablet15 mg/1oralLupin Pharmaceuticals, Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Meloxicamtablet15 mg/1oralTeva Pharmaceuticals USA Inc2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralUnichem Pharmaceuticals (USA), Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMedsource Pharmaceuticals2009-12-01Not applicableUs
Meloxicamtablet15 mg/1oralNorthwind Pharmaceuticals2014-04-02Not applicableUs
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralProficient Rx LP2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-10-02Not applicableUs
Meloxicamtablet15 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AchefreeAchefree
ActicamAcromax Dominicana
AflamidAnchor
AfloxxLusa
AglanZentiva
AinecoxCheminter
AldoronIvax
AlentumLafrancol
AlgiflexBiogen
AliviodolCentrum
AnaxicamCaferma
AnposelMedipharm
AntrendLabormed
AponipPharmatec
ArelogerGerard
AremilMagma
ArmexQintar Pharma
ArroxXepa-Soul Pattinson
ArsitecArsmedendi
ArtexPharmedic
ArthrobicMekophar
ArthroxPharmanel
ArticamStandpharm
ArtiproHelix
ArtricloxGarmisch
ArtrifilmG&R
ArtriflamSherfarma
ArtrilomPro.Med.CS
ArtriloxCombiphar
ArtroxPharmaBrand
AspicamBiofarm
AtiflamDoctor Andreu
AtrozanPharmstandard
AuroxicamAurora
AxiusHersil
Brand mixtures
NameLabellerIngredients
Trepoxicam-7.5Physician Therapeutics Llc
SaltsNot Available
Categories
UNIIVG2QF83CGL
CAS number71125-38-7
WeightAverage: 351.401
Monoisotopic: 351.034747299
Chemical FormulaC14H13N3O4S2
InChI KeyInChIKey=ZRVUJXDFFKFLMG-UHFFFAOYSA-N
InChI
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassNot Available
Direct ParentBenzothiazines
Alternative Parents
Substituents
  • N-arylamide
  • Benzothiazine
  • 2,5-disubstituted 1,3-thiazole
  • Benzenoid
  • Ortho-thiazine
  • Heteroaromatic compound
  • Vinylogous acid
  • Thiazole
  • Sulfonic acid derivative
  • Sulfonamide
  • Azole
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor symptomatic treatment of arthritis and osteoarthritis.
PharmacodynamicsMeloxicam is an nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Prostaglandins are substances that contribute to inflammation of joints. Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) and leads to a decrease of the synthesis of prostaglandins, therefore, inflammation is reduced.
Mechanism of actionAnti-inflammatory effects of meloxicam are believed to be due to inhibition of prostaglandin synthetase (cylooxygenase), leading to the inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis may be associated with the analgesic and antipyretic effects of meloxicam.
Related Articles
AbsorptionAbsolute bioavailability = 89%
Volume of distribution
  • 10 L
Protein binding99.4% bound, primarily to albumin
Metabolism

Meloxicam is almost completely metabolized into inactive metabolites by the cytochrome P450 (CYP450) isozymes. CYP2C9 is primarily responsible for metabolism of meloxicam while CYP3A4 plays a minor role. An intermediate metabolite, 5'-hydroxymethyl meloxicam, is further metabolized to 5'-carboxy meloxicam, the major metabolite. Peroxidase activity is thought to produce the two other inactive metabolites of meloxicam.

SubstrateEnzymesProduct
Meloxicam
Not Available
5'-carboxy meloxicamDetails
Meloxicam
Not Available
5'-hydroxymethyl meloxicamDetails
Route of eliminationMeloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.
Half life15-20 hours
Clearance
  • 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets]
  • 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules]
  • 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules]
  • 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules]
  • 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
ToxicityLD50, Acute: 84 mg/kg (Rat); Oral 470 mg/kg (Mouse); Oral 320 mg/kg (Rabbit)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Meloxicam Action PathwayDrug actionSMP00106
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9811
Caco-2 permeable+0.8484
P-glycoprotein substrateSubstrate0.5181
P-glycoprotein inhibitor INon-inhibitor0.7516
P-glycoprotein inhibitor IINon-inhibitor0.7491
Renal organic cation transporterNon-inhibitor0.9275
CYP450 2C9 substrateSubstrate0.5637
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.6649
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5511
CYP450 2D6 inhibitorNon-inhibitor0.9322
CYP450 2C19 inhibitorNon-inhibitor0.8948
CYP450 3A4 inhibitorNon-inhibitor0.8191
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7316
Ames testNon AMES toxic0.8576
CarcinogenicityNon-carcinogens0.7052
BiodegradationNot ready biodegradable0.9312
Rat acute toxicity3.4619 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9579
hERG inhibition (predictor II)Non-inhibitor0.7999
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Beijing yabao biopharmaceutical co ltd
  • Breckenridge pharmaceutical inc
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Corepharma llc
  • Dr reddys laboratories inc
  • Genpharm inc
  • Glenmark generics ltd
  • Lupin pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Strides arcolab ltd
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Unichem laboratories ltd
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral15.0 mg
Kit
Suspensionoral7.5 mg/5mL
Tablet7.5 mg/1
Tabletoral15 mg/1
Tabletoral7.5 mg/1
Tabletoral15 mg
Tabletoral7.5 mg
Kit
Capsuleoral10 mg/1
Capsuleoral5 mg/1
Prices
Unit descriptionCostUnit
Meloxicam 7.5 mg/5ml Suspension 100ml Bottle86.99USD bottle
Meloxicam bp powder56.61USD g
Mobic 15 mg tablet7.37USD tablet
Meloxicam 15 mg tablet4.94USD tablet
Mobic 7.5 mg tablet4.74USD tablet
Meloxicam 7.5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6184220 Yes1999-09-252019-09-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254 dec °CPhysProp
water solubility7.15 mg/LNot Available
logP3.43AVDEEF,A (1997)
Caco2 permeability-4.71ADME Research, USCD
pKa4.08MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP2.28ALOGPS
logP1.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.47ChemAxon
pKa (Strongest Basic)0.47ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity88.62 m3·mol-1ChemAxon
Polarizability34.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Laura Coppi, “Crystalline forms of meloxicam and processes for their preparation and interconversion.” U.S. Patent US20030109701, issued June 12, 2003.

US20030109701
General ReferencesNot Available
External Links
ATC CodesM01AC56M01AC06
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (45.4 KB)
MSDSDownload (35.7 KB)
Interactions
Drug Interactions
Drug
AbciximabMeloxicam may increase the anticoagulant activities of Abciximab.
AcenocoumarolMeloxicam may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Acetylsalicylic acid.
AliskirenMeloxicam may decrease the antihypertensive activities of Aliskiren.
AlteplaseMeloxicam may increase the anticoagulant activities of Alteplase.
AmikacinMeloxicam may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmitriptylineAmitriptyline may increase the antiplatelet activities of Meloxicam.
AnistreplaseMeloxicam may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Meloxicam is combined with Apixaban.
ArbekacinMeloxicam may decrease the excretion rate of Arbekacin which could result in a lower serum level and potentially a reduction in efficacy.
BalsalazideMeloxicam may increase the nephrotoxic activities of Balsalazide.
CeritinibThe serum concentration of Meloxicam can be increased when it is combined with Ceritinib.
Citric AcidMeloxicam may increase the anticoagulant activities of Citric Acid.
ColesevelamColesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Meloxicam is combined with Collagenase.
CyclosporineMeloxicam may increase the nephrotoxic activities of Cyclosporine.
Dabigatran etexilateMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.
DalteparinMeloxicam may increase the anticoagulant activities of Dalteparin.
DasatinibDasatinib may increase the anticoagulant activities of Meloxicam.
DeferasiroxThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deoxycholic Acid.
DesmopressinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meloxicam.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.
DicoumarolMeloxicam may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meloxicam.
DrospirenoneMeloxicam may increase the hyperkalemic activities of Drospirenone.
Edetic AcidMeloxicam may increase the anticoagulant activities of Edetic Acid.
EnoxaparinMeloxicam may increase the anticoagulant activities of Enoxaparin.
EplerenoneMeloxicam may decrease the antihypertensive activities of Eplerenone.
Ethyl biscoumacetateMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meloxicam.
FloxuridineThe metabolism of Meloxicam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Meloxicam can be decreased when combined with Fluconazole.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Meloxicam.
Fondaparinux sodiumMeloxicam may increase the anticoagulant activities of Fondaparinux sodium.
FramycetinMeloxicam may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
GentamicinMeloxicam may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Meloxicam.
HaloperidolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
HeparinMeloxicam may increase the anticoagulant activities of Heparin.
HydralazineMeloxicam may decrease the antihypertensive activities of Hydralazine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Meloxicam.
IcosapentThe risk or severity of adverse effects can be increased when Meloxicam is combined with Icosapent.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Meloxicam.
ItraconazoleThe serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.
KanamycinMeloxicam may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.
LimaprostLimaprost may increase the antiplatelet activities of Meloxicam.
LithiumThe serum concentration of Lithium can be increased when it is combined with Meloxicam.
LumacaftorThe serum concentration of Meloxicam can be decreased when it is combined with Lumacaftor.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meloxicam.
MifepristoneThe serum concentration of Meloxicam can be increased when it is combined with Mifepristone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meloxicam.
NadololMeloxicam may decrease the antihypertensive activities of Nadolol.
NeomycinMeloxicam may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NetilmicinMeloxicam may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
ObinutuzumabThe risk or severity of adverse effects can be increased when Meloxicam is combined with Obinutuzumab.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Homoharringtonine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Meloxicam.
PamidronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
ParoxetineParoxetine may increase the antiplatelet activities of Meloxicam.
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Meloxicam.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Meloxicam.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Meloxicam.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Meloxicam.
PhenindioneMeloxicam may increase the anticoagulant activities of Phenindione.
PhenprocoumonMeloxicam may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Meloxicam can be increased when combined with Phenytoin.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Polystyrene sulfonate.
PorfimerMeloxicam may increase the photosensitizing activities of Porfimer.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meloxicam.
ProbenecidThe serum concentration of Meloxicam can be increased when it is combined with Probenecid.
ReteplaseMeloxicam may increase the anticoagulant activities of Reteplase.
RibostamycinMeloxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelMeloxicam may increase the anticoagulant activities of Ridogrel.
RivaroxabanMeloxicam may increase the anticoagulant activities of Rivaroxaban.
SecobarbitalThe metabolism of Meloxicam can be increased when combined with Secobarbital.
SparfloxacinMeloxicam may increase the neuroexcitatory activities of Sparfloxacin.
SpectinomycinMeloxicam may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptokinaseMeloxicam may increase the anticoagulant activities of Streptokinase.
StreptomycinMeloxicam may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulfisoxazoleThe metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.
SulodexideMeloxicam may increase the anticoagulant activities of Sulodexide.
TacrolimusMeloxicam may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meloxicam.
TenecteplaseMeloxicam may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tenofovir.
TipranavirTipranavir may increase the antiplatelet activities of Meloxicam.
TobramycinMeloxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideMeloxicam may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tositumomab.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.
TriamtereneMeloxicam may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meloxicam.
UrokinaseMeloxicam may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Meloxicam.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meloxicam.
VenlafaxineVenlafaxine may increase the antiplatelet activities of Meloxicam.
VerteporfinMeloxicam may increase the photosensitizing activities of Verteporfin.
Vitamin EVitamin E may increase the antiplatelet activities of Meloxicam.
VoriconazoleThe serum concentration of Meloxicam can be increased when it is combined with Voriconazole.
WarfarinMeloxicam may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100. [PubMed:10220944 ]
  2. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44. [PubMed:10340919 ]
  3. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  4. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787 ]
  5. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension. 1999 Nov;34(5):1163-7. [PubMed:10567199 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314 ]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314 ]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:
PGD
Uniprot ID:
P52209
Molecular Weight:
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T: Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96. Epub 2007 Oct 16. [PubMed:17939016 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 24, 2016 03:05